Simple Blood Index Predicts Survival in Kidney Cancer, Meta-Analysis Finds

A composite blood test that blends inflammation, nutrition, and immune status into a single number appears to carry real prognostic weight in kidney cancer, according to a new systematic review and meta-analysis published in Frontiers in Oncology. Researchers in China pooled data from five retrospective cohort studies totaling 587 patients with renal cell carcinoma (RCC) and found that those with a low C-reactive protein-albumin-lymphocyte (CALLY) index faced roughly a threefold higher risk of disease progression and more than a twofold higher risk of death compared with patients whose index was high.

The CALLY index is calculated from three laboratory values that almost every hospital already measures: serum C-reactive protein (CRP), serum albumin, and the absolute lymphocyte count. The formula multiplies albumin by the lymphocyte count and divides by CRP, scaled by a fixed numerical factor. In one stroke, the index captures three distinct dimensions of the host-tumor relationship. CRP reflects systemic inflammatory activity, a process that can fuel tumor-cell proliferation, angiogenesis, invasion, and immune dysregulation. Albumin serves as a proxy for nutritional reserve while also being depressed by inflammation-driven metabolic changes. Lymphocyte counts gauge the immune competence of the patient, since lymphopenia may signal an impaired capacity for antitumor immune surveillance.

The index was first introduced as a prognostic marker in hepatocellular carcinoma and has since been examined in a range of malignancies. In RCC, a disease that accounts for roughly 2 percent of all cancers worldwide and remains among the most lethal urological malignancies, conventional predictors such as TNM stage, histological grade, and tumor size leave considerable variation in individual outcomes unexplained. That gap has driven interest in accessible blood-based biomarkers, including the neutrophil-to-lymphocyte ratio, the platelet-to-lymphocyte ratio, the systemic inflammation index, and the prognostic nutritional index. Most of these capture only one component of the host response, which is precisely the limitation the CALLY index was designed to overcome.

The research team, led by Yuxuan Lin of the Department of Pharmacy at Guangxi Hospital Division of The First Affiliated Hospital of Sun Yat-sen University, registered the review prospectively in PROSPERO and followed the PRISMA 2020 reporting guidelines. They searched PubMed and Embase from database inception to August 2026, screened 32 records, and ultimately included five retrospective cohort studies published between 2024 and 2026, with sample sizes ranging from 68 to 253 patients. Two studies came from Japan and three from Turkey. Two cohorts focused on localized disease, exclusively clear cell RCC, while three examined metastatic RCC with mixed histological subtypes.

The pooled hazard ratio for progression-free survival was 2.89, with a 95 percent confidence interval of 1.82 to 4.58 and low statistical heterogeneity, an I-squared of 24.7 percent. For overall survival, the pooled hazard ratio was 2.32, with a 95 percent confidence interval of 1.61 to 3.35 and essentially no heterogeneity, with I-squared at 0 percent. Because all hazard ratios were oriented to a common direction, values above 1.0 indicate higher risk among patients with a low CALLY index. Leave-one-out sensitivity analyses confirmed that no single study drove the pooled results, and the estimates remained above the null throughout.

One statistical nuance deserves attention. The 95 percent prediction interval for progression-free survival, which estimates the range of effects plausible in a future comparable study, spanned 0.84 to 9.98 and therefore included the null value of 1.0. For overall survival, the prediction interval was 1.30 to 4.17 and excluded the null, suggesting the survival association is more consistent across populations. The wider uncertainty for progression-free survival likely reflects the fact that the endpoint itself meant different things in different studies: postoperative recurrence in localized cohorts versus progression during systemic therapy in metastatic cohorts, definitions that are not directly equivalent.

Subgroup analyses compared localized/clear cell populations with metastatic/mixed-histology populations. For progression-free survival, the pooled hazard ratio was 4.89 in the localized subgroup and 2.34 in the metastatic subgroup, but the difference between subgroups was not statistically significant, with a P value of 0.112. For overall survival, the estimates were 2.59 and 2.30 respectively, with no evidence of a subgroup difference at P equals 0.847. The authors stress that because disease stage, histological composition, and treatment setting were closely aligned across the available studies, these analyses cannot disentangle the independent effects of any single characteristic. The apparent stronger association in localized disease remains exploratory.

Methodological variation across the five studies complicates interpretation. Two Japanese studies used a CALLY formulation without the 10-to-the-fourth scaling factor, while the three Turkish studies used the scaled version. When laboratory units are equivalent, these formulations differ only by a fixed numerical factor, so the relative ranking of patients is unchanged, but the reported cut-off values differ dramatically. Even among studies using the same convention, cut-offs varied, derived by maximal log-rank statistics, the Youden index, or cohort-based distributional criteria. Timing of measurement also differed: the localized cohorts measured CALLY after nephrectomy, where values may be influenced by surgical trauma and acute inflammatory responses, while the metastatic cohorts measured it before starting systemic therapy, where the index may instead reflect tumor burden and baseline host status.

All five studies scored 8 to 9 stars on the Newcastle-Ottawa Scale, indicating high methodological quality, and most pooled estimates came from multivariable models adjusting for established prognostic factors such as IMDC risk group, Fuhrman grade, and metastatic sites. Still, the authors caution that the covariates differed across studies, one progression-free survival estimate was univariable, and residual confounding cannot be excluded. A prognostic association does not establish a causal role for CALLY in disease progression; each component of the index is nonspecific and can be altered by infection, inflammatory comorbidities, nutrition, organ function, and treatment effects. The index should currently be viewed as a marker of broader systemic condition rather than a direct measure of tumor immunity.

From a practical standpoint, the appeal of the CALLY index is its simplicity. It requires no specialized equipment, and its components are routinely available during standard clinical evaluation, making it feasible across diverse healthcare settings. It could potentially complement established frameworks such as the IMDC and MSKCC criteria in metastatic disease, and several included studies reported associations that persisted after adjustment for those risk scores. However, the authors are explicit that the current evidence does not support using CALLY alone to select therapy, change surveillance schedules, or make treatment decisions. Demonstrating clinical utility requires showing that adding CALLY to existing models improves discrimination, calibration, risk reclassification, and ultimately decision-making. The authors call for large, prospective, multicenter studies with standardized blood sampling protocols, prespecified and externally validated RCC-specific thresholds, investigation of serial CALLY measurements over time, and evaluation in non-clear-cell subtypes, which remain underrepresented in the current literature. Until then, the index stands as a promising but unproven adjunct in the prognostic toolkit for kidney cancer.

Subject of Research: Prognostic value of the CALLY index for survival outcomes in renal cell carcinoma

Article Title: C-reactive protein-albumin-lymphocyte index and survival outcomes in renal cell carcinoma: a systematic review and meta-analysis

Article References: Wei, Y., Mai, L., Zhang, X., Zhang, Y., & Lin, Y. (2026). C-reactive protein-albumin-lymphocyte index and survival outcomes in renal cell carcinoma: a systematic review and meta-analysis. Frontiers in Oncology, 16, 1994071. https://doi.org/10.3389/fonc.2026.1994071

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1994071

Keywords: renal cell carcinoma, CALLY index, meta-analysis, systematic review, prognosis, biomarker, progression-free survival, overall survival, systemic inflammation, C-reactive protein, albumin, lymphocyte count